Table 4

Diastolic parameters of Fabry cohort by echocardiography

Post-treatmentBaselineYear 1Year 2Year 5Year 7Year 10
DT (ms)
 Non-CKD5216±21214±33211±33198±37215±35219±33
 CKD5264±81274±81251±69258±80260±64315±161
IVRT (ms)
 Non-CKD592±1885±1083±1480±1293±1186±13
 CKD599±16101±1599±23114±22105±35101±14
E/A
 Non-CKD51.66±0.591.88±0.891.89±0.801.71±0.571.73±0.771.40±0.41
 CKD51.12±0.291.06±0.171.32±0.281.27±0.271.03±0.241.29±0.38
E/Ea
 Non-CKD510.8±6.010.6±5.510.3±4.211.1±3.610.4±3.410.2±3.2
 CKD515.7±8.715.8±8.716.1±9.315.8±8.321.8±12.921.2±8.2
  • Non-CKD5 cohort size: baseline (N=15), year 1 (N=15), year 2 (N=15), year 5 (N=12), year 7 (N=12) and year 10 (N=12).

  • CKD5 cohort size: baseline (N=10), year 1 (N=9), year 2 (N=10), year 5 (N=6), year 7 (N=6) and year 10 (N=5).

  • Two-way ANOVA comparing CKD5 with non-CKD5 for parameters DT, IVRT, E/A and E/Ea over the duration of treatment were all statistically different (p<0.0001).

  • ANOVA, analysis of variance; CKD5, chronic kidney disease stage 5; DT, deceleration time; E/Ea, estimated LV filling pressure; IVRT, isovolumetric relaxation time.